Jaclyn F. Hechtman

2012–2025 年に発表

82
論文数
22,031
被引用数
55
h 指数
79
i10 指数

被引用数

Jaclyn F. Hechtman の年別被引用数1992 年: 被引用 1 件1998 年: 被引用 3 件2000 年: 被引用 1 件2009 年: 被引用 2 件2011 年: 被引用 1 件2013 年: 被引用 2 件2014 年: 被引用 1 件2015 年: 被引用 33 件2016 年: 被引用 79 件2017 年: 被引用 153 件2018 年: 被引用 342 件2019 年: 被引用 1,221 件2020 年: 被引用 1,799 件2021 年: 被引用 1,776 件2022 年: 被引用 1,455 件2023 年: 被引用 959 件2024 年: 被引用 1,299 件2025 年: 被引用 569 件2026 年: 被引用 18 件1993〜1997 年は被引用が無いため表示していません1999 年は被引用が無いため表示していません2001〜2008 年は被引用が無いため表示していません2010 年は被引用が無いため表示していません2012 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,670 件、この内訳の 29.7%中国: 引用元論文 1,321 件、この内訳の 10.7%イタリア: 引用元論文 759 件、この内訳の 6.1%イギリス: 引用元論文 654 件、この内訳の 5.3%ドイツ: 引用元論文 620 件、この内訳の 5%日本: 引用元論文 526 件、この内訳の 4.3%フランス: 引用元論文 493 件、この内訳の 4%スペイン: 引用元論文 428 件、この内訳の 3.5%カナダ: 引用元論文 381 件、この内訳の 3.1%オランダ: 引用元論文 327 件、この内訳の 2.6%オーストラリア: 引用元論文 270 件、この内訳の 2.2%スイス: 引用元論文 265 件、この内訳の 2.1%
0%29.7%その他 21.4%

分野

  • Medicine70%
  • Biochemistry, Genetics and Molecular Biology25.8%
  • Immunology and Microbiology1.7%
  • Computer Science1.1%
  • Neuroscience0.3%
  • Chemistry0.2%
  • その他0.9%

トピック

  • Cancer Genomics and Diagnostics9.2%
  • Cancer Immunotherapy and Biomarkers6.1%
  • Lung Cancer Treatments and Mutations4.8%
  • Genetic factors in colorectal cancer4.7%
  • Colorectal Cancer Treatments and Studies3.6%
  • Pancreatic and Hepatic Oncology Research2.7%
  • その他68.9%

共著者

全論文

検索で開く
  1. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Laetitia Borsu, Justyna Sadowska, Jacklyn Casanova, Ruben Bacares, Iwona Kiecka, Anna Razumova, Julie B Son, Lisa Stewart, Tessara Baldi, Kerry Mullaney, Hikmat Al‐Ahmadie, Efsevia Vakiani, Adam Abeshouse, Alexander Penson, Philip Jonsson, Niedzica Camacho, Matthew T. Chang, Helen Won, Benjamin Groß, Ritika Kundra, Zachary Heins, Hsiao‐Wei Chen, Sarah Phillips, Hongxin Zhang, Jiaojiao Wang, Angelica Ochoa, Jonathan Wills, Michael Eubank, Stacy B. Thomas, Stuart M. Gardos, Dalicia N. Reales, Jesse Galle, Robert Durany, Roy Cambria, Wassim Abida, Andrea Cercek, Darren R. Feldman, Mrinal M. Gounder, A. Ari Hakimi, James J. Harding, Gopa Iyer, Yelena Y. Janjigian, Emmet Jordan, Ciara M. Kelly, Maeve A. Lowery, Luc G.T. Morris, Antonio Omuro, Nitya Raj, Pedram Razavi, Alexander N. Shoushtari, Neerav Shukla, Tara E. Soumerai, Anna M. Varghese, Rona Yaeger, Jonathan Coleman, Bernard H. Bochner, Gregory J. Riely, Leonard B. Saltz, Howard I. Scher, Paul Sabbatini, Mark E. Robson, David S. Klimstra, Barry S. Taylor, José Baselga, Nikolaus Schultz, David M. Hyman, Maria E. Arcila, David B. Solit, Marc Ladanyi, Michael F. Berger - Nature Medicine 2017 被引用: 3,517

  2. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Molecular Diagnostics 2015 被引用: 2,155

  3. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brian B. Tuch, Kevin Ebata, Scott Cruickshank, Nora Ku, Michael C. Cox, Douglas S. Hawkins, David S. Hong, David M. Hyman - New England Journal of Medicine 2018 被引用: 2,728

  4. Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2018 被引用: 864

  5. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Howard I. Scher - JAMA Oncology 2018 被引用: 663

  6. Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies

    著者: , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2018 被引用: 592

  7. Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Science 2019 被引用: 581

  8. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention

    著者: , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2018 被引用: 578

  9. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martin R. Weiser, Julio García Aguilar, David S. Klimstra, Luis A. Díaz, José Baselga, Liying Zhang, Marc Ladanyi, David M. Hyman, David B. Solit, Mark E. Robson, Barry S. Taylor, Kenneth Offit, Michael F. Berger, Zsofia K. Stadler - Journal of Clinical Oncology 2018 被引用: 627

  10. Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data

    著者: , , , , , , , , , , , , , , - JCO Precision Oncology 2017 被引用: 381

  11. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fang‐Shu Ou, Laura Porter, Kanwal Raghav, Deborah Schrag, Aaron J. Scott, Qian Shi, John H. Strickler, Alan P. Venook, Rona Yaeger, Greg Yothers, Y. Nancy You, Jason A. Zell, Scott Kopetz - Nature Reviews Clinical Oncology 2020 被引用: 365

  12. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 357

  13. Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David M. Hyman, Maurizio Scaltriti, Marc Ladanyi, Neal Rosen, David H. Ilson, Michael F. Berger, Laura H. Tang, Barry S. Taylor, David B. Solit, Nikolaus Schultz - Cancer Discovery 2017 被引用: 382

  14. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

    著者: , , , , , , , , , , , , , - Modern Pathology 2019 被引用: 537

  15. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alan Li, Emily S. Lebow, Anita S. Bowman, Donna C. Ferguson, Ying Liu, Douglas A. Mata, Rohit Sharma, Soo‐Ryum Yang, Tejus Bale, Jamal Benhamida, Jason C. Chang, Snjezana Doğan, Meera Hameed, Jaclyn F. Hechtman, Christine Moung, Dara S. Ross, Efsevia Vakiani, Chad Vanderbilt, JinJuan Yao, Pedram Razavi, Lillian M. Smyth, Sarat Chandarlapaty, Gopa Iyer, Wassim Abida, James J. Harding, Benjamin A. Krantz, Eileen M. O’Reilly, Helena A. Yu, Bob T. Li, Charles M. Rudin, Luis A. Díaz, David B. Solit, Maria E. Arcila, Marc Ladanyi, Brian Houck‐Loomis, Dana W.Y. Tsui, Michael F. Berger, Ahmet Zehir, Ryma Benayed - Nature Communications 2021 被引用: 183

  16. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Barry S. Taylor, Steve Andrews, S. Michael Rothenberg, David M. Hyman - Cancer Discovery 2017 被引用: 433

  17. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rohit Chandwani, William R. Jarnagin - Hepatology 2021 被引用: 162

  18. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research

    著者: , , , , , , , , , , , - Annals of Oncology 2019 被引用: 360

  19. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Filippo de Braud, Chiara Cremolini - JNCI Journal of the National Cancer Institute 2017 被引用: 324

  20. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2018 被引用: 283

  21. EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2 -Amplified Esophagogastric Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael F. Berger, Elisa de Stanchina, Barry S. Taylor, Jason S. Lewis, David B. Solit, Jorge A. Carrasquillo, Maurizio Scaltriti, Nikolaus Schultz, Yelena Y. Janjigian - Cancer Discovery 2018 被引用: 147

  22. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 被引用: 124

  23. Lineage Reversion Drives WNT Independence in Intestinal Cancer

    著者: , , , , , , , , , , , , , - Cancer Discovery 2020 被引用: 83

  24. Carcinomas assemble a filamentous CXCL12–keratin-19 coating that suppresses T cell–mediated immune attack

    著者: , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2022 被引用: 70